EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation

Rohit Pal iD, Gurubasavaraja Swamy Purawarga Matada, Ghanshyam Teli, Md Jawaid Akhtar iD, Bhupinder Kumar

Chemistry & Biodiversity · 2025-09 · 22 (9)

DOI: 10.1002/cbdv.202500549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, online erschienen am 03.05.2025. Verfasst von Rohit Pal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, India. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Pyrimidines, Antineoplastic Agents, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 52 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) mutations, especially in non–small cell lung cancer (NSCLC), present significant challenges to targeted therapies due to acquired resistance. This study reports the synthesis and evaluation of a series of 4‐(2‐substituted‐6‐(furan‐2‐yl)pyrimidin‐4‐yl)‐substituted phenyl derivatives as potential anticancer agents. The compounds were screened using MTT and brine shrimp lethality assays, identifying R2 , R10 , and R12 as the most potent against NSCLC cell lines, particularly NCI‐H522 and NCI‐H1975. Compound R12 was most potent and selective against NCI‐H522, with an IC 50 value of 0.95 ± 0.02 µM as compared to standard afatinib (IC 50 = 1.86 ± 0.22 µM). EGFR inhibition assays confirmed R12 effectiveness with IC 50 values of 1.62 ± 0.15 µM, 0.49 ± 0.23 µM, and 0.98 ± 0.02 µM against EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S , respectively. The compound R12 led to the cell cycle arrest in the G2/M and S phase of NCI‐H522 cells with an increase in apoptosis. Molecular docking studies showed R12 high binding affinity (Δ G = −10.2 kcal/mol for EGFR WT ; K i = 32.73 nM) and significant interactions with key amino acids in the active site. Molecular dynamics simulations demonstrated stable protein–ligand interactions with low RMSD (0.17–0.27 nm) and significant eigenvalue (1.706 × 10 −4 ). Compound R12 also exhibited antioxidant properties against DPPH (IC 50 = 12.11 ± 8.96 µM) and H 2 O 2 (IC 50 = 8.89 ± 1.72 µM). Furthermore, DFT analysis and ADMET predictions indicated that R12 possesses favorable physiochemical and pharmacokinetic properties, suggesting high bioavailability and minimal toxicity. These findings emphasize R12 as a promising lead for further preclinical investigation in overcoming EGFR mutations, including the challenging triple mutation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungPyrimidinesAntineoplastic AgentsDrug DesignProtein Kinase InhibitorsFuransLung NeoplasmsHumansErbB ReceptorsStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular Docking SimulationCell Line, TumorCell ProliferationMolecular StructureAnimalsDose-Response Relationship, DrugApoptosis

Stichwörter der Autor:innen

EGFRNSCLCanticancermolecular dynamicspyrimidine linked furan

Substanzen

ErbB ReceptorsPyrimidinesAntineoplastic AgentsProtein Kinase InhibitorsEGFR protein, humanFuranspyrimidine

Autor:innen und Institutionen

  • Department of Pharmaceutical Chemistry, Integrated Drug Discovery Centre, Acharya & BM Reddy College of Pharmacy, Bengaluru, India.
  • School of Pharmacy, Sangam University, Bhilwara, India.
  • Department of Pharmaceutical Chemistry, National University of Science and Technology, Muscat, Oman.
  • Department of Pharmaceutical Sciences, HNB Garhwal University, Chauras Campus, Srinagar, India.

ORCID-Profile: Rohit Pal, Md Jawaid Akhtar

Zitieren

APA

Pal, R., Matada, G. S. P., Teli, G., Akhtar, M. J., & Kumar, B. (2025). Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation. Chemistry & Biodiversity, 22(9). https://doi.org/10.1002/cbdv.202500549

Vancouver

Pal R, Matada GSP, Teli G, Akhtar MJ, Kumar B. Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation. Chemistry & Biodiversity. 2025;22(9). doi:10.1002/cbdv.202500549

BibTeX
@article{Pal2025,
  author = {Pal, Rohit and Matada, Gurubasavaraja Swamy Purawarga and Teli, Ghanshyam and Akhtar, Md Jawaid and Kumar, Bhupinder},
  title = {Design, Synthesis, and Molecular Profiling of Pyrimidine‐Furan Derivatives Targeting EGFR WT , EGFR T790M , and EGFR L858R/T790M/C797S in NSCLC: In Vitro and In Silico Evaluation},
  journal = {Chemistry & Biodiversity},
  year = {2025},
  volume = {22},
  number = {9},
  doi = {10.1002/cbdv.202500549}
}
Kostenlos starten →